Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vytorin and Fenofibrate in Mixed Hyperlipidemia
NCT00093899Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Nov 2004
- Primary completion
- Sep 2005
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
01
Overview
Phase 3, randomised, double-blind trial of Vytorin in mixed hyperlipidemia (4 arms), sponsored by Organon & Co. Primary endpoint: Plasma Low-Density Lipoprotein Cholesterol at 24 weeks. Started Nov 2004; status: completed.
02
Drugs
Vytorin
03
Conditions
mixed hyperlipidemia
Beyond the preview
Go deeper on NCT00093899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00093899.